<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-title>BMC Cancer</journal-title><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2407-7-60</article-id><article-id pub-id-type="pmid">17411440</article-id><article-id pub-id-type="doi">10.1186/1471-2407-7-60</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Ovarian cancer risk and common variation in the sex hormone-binding globulin gene: a population-based case-control study</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Garcia-Closas</surname><given-names>Montserrat</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>montse@nih.gov</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Brinton</surname><given-names>Louise A</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>brintonl@exchange.nih.gov</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Lissowska</surname><given-names>Jolanta</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>lissowsj@coi.waw.pl</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Richesson</surname><given-names>Douglas</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>richessond@mail.nih.gov</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Sherman</surname><given-names>Mark E</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>shermanm@exchange.nih.gov</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Szeszenia-Dabrowska</surname><given-names>Neonila</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>wies@porta.imp.lodz.pl</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Peplonska</surname><given-names>Beata</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>beatap@imp.lodz.pl</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Welch</surname><given-names>Robert</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>welchr@mail.nih.gov</email></contrib><contrib id="A9" contrib-type="author"><name><surname>Yeager</surname><given-names>Meredith</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>yeagerm@mail.nih.gov</email></contrib><contrib id="A10" contrib-type="author"><name><surname>Zatonski</surname><given-names>Witold</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>zatonskiw@coi.waw.pl</email></contrib><contrib id="A11" contrib-type="author"><name><surname>Chanock</surname><given-names>Stephen J</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>chanocks@exchange.nih.gov</email></contrib></contrib-group><aff id="I1"><label>1</label>Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, 6120 Executive Boulevard, suite 550, Rockville, MD 20952-7234, USA</aff><aff id="I2"><label>2</label>Core Genotyping Facility, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, USA</aff><aff id="I3"><label>3</label>Department of Cancer Epidemiology and Prevention, M. Sklodowska-Curie Institute of Oncology and Cancer Center, Warsaw, Poland</aff><aff id="I4"><label>4</label>Department of Occupational and Environmental Epidemiology, Nofer Institute of Occupational Medicine, Lodz, Poland</aff><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>5</day><month>4</month><year>2007</year></pub-date><volume>7</volume><fpage>60</fpage><lpage>60</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/7/60"/><history><date date-type="received"><day>11</day><month>11</month><year>2006</year></date><date date-type="accepted"><day>5</day><month>4</month><year>2007</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2007 Garcia-Closas et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2007</copyright-year><copyright-holder>Garcia-Closas et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> Garcia-Closas Montserrat montse@nih.gov </dc:author><dc:title> Ovarian cancer risk and common variation in the sex hormone-binding globulin gene: a population-based case-control study </dc:title><dc:date>2007</dc:date><dcterms:bibliographicCitation>BMC Cancer 7(1): 60-. (2007)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2407(2007)7:1&#x0003c;60&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2407</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>The sex hormone-binding globulin (<italic>SHBG</italic>) is a carrier protein that modulates the bio-availability of serum sex steroid hormones, which may be involved in ovarian cancer. We evaluated whether common genetic variation in <italic>SHBG </italic>and its 3' neighbor <italic>ATP1B2</italic>, in linkage disequilibrium, is associated with the risk of epithelial ovarian cancer.</p></sec><sec sec-type="methods"><title>Methods</title><p>The study population included 264 women with ovarian carcinoma and 625 controls participating in a population-based case-control study in Poland. Five common single nucleotide polymorphisms (SNPs) in <italic>SHGB </italic>and five in <italic>ATP1B2 </italic>were selected to capture most common variation in this region.</p></sec><sec><title>Results</title><p>None of the SNPs evaluated was significantly associated with ovarian cancer risk, including the putative functional SNPs <italic>SHBG </italic>D356N (rs6259) and -67G&#x0003e;A 5'UTR (rs1799941). However, our data were consistent with a decreased ovarian cancer risk associated with the variant alleles for these two SNPs, which have been previously associated with increased circulating levels of SHBG.</p></sec><sec><title>Conclusion</title><p>These data do not support a substantial association between common genetic variation in <italic>SHBG </italic>and ovarian cancer risk.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Hormonal stimulation of ovarian epithelial cells has been proposed as a mechanism for carcinogenesis of the ovaries [<xref ref-type="bibr" rid="B1">1</xref>]. The evidence for sex steroid hormones playing a role in ovarian cancer is primarily indirect, based on animal and <italic>in vitro </italic>studies, as well epidemiological observations [<xref ref-type="bibr" rid="B1">1</xref>], while the relationship between circulating levels of sex steroids and ovarian cancer risk has not been clearly demonstrated [<xref ref-type="bibr" rid="B2">2</xref>,<xref ref-type="bibr" rid="B3">3</xref>].</p><p>The sex steroid hormone-binding globulin (<italic>SHBG</italic>) gene regulates the action of sex steroid hormones by modulating their bioavailability to target tissues such as the ovaries [<xref ref-type="bibr" rid="B4">4</xref>]. The <italic>SHBG </italic>gene is located on the short arm of chromosome 17. A non-synonymous SNP in exon 8 results in an amino acid substitution of asparagine for aspartic acid (D356N, rs6259) in the SHBG protein, and the asparagine (N) allele of <italic>SHBG </italic>has been associated with elevated circulating levels of SHBG in post-menopausal women [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B7">7</xref>]. An additional SNP in the 5' untranslated region (UTR) of <italic>SHBG </italic>has also been associated with elevated <italic>SHBG </italic>levels [<xref ref-type="bibr" rid="B6">6</xref>]. These data suggest that common variation in <italic>SHBG </italic>has functional relevance and thus, could affect the risk of hormonally-related cancers.</p><p>We performed a detailed assessment of common genetic variation in <italic>SHBG </italic>and evaluated the possibility of an association with ovarian cancer risk in the Polish Ovarian Cancer Study. We included SNPs in the <italic>SHBG </italic>3' flanking gene ATPase, Na+/K+ transporting beta 2 polypeptide (<italic>ATP1B2</italic>) because of the observation of linkage disequilibrium (LD) that extends across <italic>SHBG </italic>and <italic>ATP1B2 </italic>based on a re-sequencing study [<xref ref-type="bibr" rid="B8">8</xref>]. The enzyme encoded by <italic>ATP1B2 </italic>is involved in establishing and maintaining the electrochemical gradients of Na and K ions across the plasma membrane. Inclusion of neighboring genes in studies of relationships between disease and common genetic variation is of interest because they could affect the regulation of the protein of interest.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Study population</title><p>The Polish Ovarian Cancer Study is a population-based case-control study of ovarian cancer conducted among female residents of Warsaw and Lodz (Poland), 20&#x02013;74 years of age. Eligible cases consisted of all women newly diagnosed with histologically confirmed ovarian carcinoma or a borderline tumor identified during the study period (June 2001 &#x02013; December 2003). We identified a total of 437 eligible cases. Most (76%) cases were idenditfied through a rapid ascertainment system in participating hospitals, and the remaining cases (24%) missed by this system were identified through cancer registries. Control women were randomly selected within matching strata from complete population lists (PESEL database) of Warsaw and Lodz residents from 2001 to 2004, and were frequency matched to cases on age (5-year groups) and study site (Warsaw and Lodz). Women who reported a previous diagnosis of ovarian cancer or bilateral oopherectomy were excluded as controls. Of the eligible cases and controls, 78% and 69%, respectively, agreed to participate in the study. The main reasons for non-participation among eligible subjects included: refusal to participate (11% cases and 24% controls); unable to locate (3% cases and 7% controls), and deceased (7% cases and &#x0003c;0.1% controls). This resulted in 341 cases and 1994 controls participating in the main study.</p><p>All participants underwent a personal interview regarding known or suspected ovarian cancer risk factors. The median time from diagnosis to interview was 2.4 months, ranging from 5 days to one year. Of the interviewed women, 315 (92%) cases and 1911 (96%) controls provided a blood or buccal cell sample for DNA extraction; however, eight of these cases were excluded because of limited amounts of DNA or quality control problems. This report is limited to carcinomas; therefore 22 cases with borderline tumors and 21 cases with non-epithelial tumors were further excluded from the analyses, leaving 264 cases (241 with blood and 23 with buccal cell DNA). For costs-efficiency, we randomly selected a sample of 625 controls with blood DNA to approximate a 1:2 case:control ratio. Thus, final analyses included a total of 264 cases and 625 controls. All study participants were of Polish Caucasian origin. The study protocol was reviewed and approved by local and NCI Institutional Review Boards (IRBs). All participants provided written informed consent.</p></sec><sec><title>Genotyping</title><p>Single nucleotide polymorphism (SNP) selection was based on a re-sequence analysis of <italic>TP53 </italic>and its neighboring genes, which include <italic>SHBG </italic>and <italic>ATP1B2</italic>, performed in 94 healthy Norwegian women and 102 individuals in the SNP500 Cancer panel [<xref ref-type="bibr" rid="B8">8</xref>]. SNPs in <italic>SHBG </italic>and <italic>ATP1B2 </italic>with a minor allele frequency &#x0003e;0.05 were identified during a re-sequence analysis of all exons, evolutionarily conserved regions and promoter regions and were genotyped in the Polish Ovarian Cancer Study. Genotype analyses were performed at the Core Genotyping Facility (CGF) of the Division of Cancer Epidemiology and Genetics, NCI for 5 SNPs in <italic>SHBG </italic>(rs1799941, -67G&#x0003e;A 5'UTR; rs6257, IVS1-17T&#x0003e;C; rs6259, Ex8+6G&#x0003e;A (D356N); rs727428, 1121 bp 3' of STP T&#x0003e;C; and rs1641544 31959 bp 3' of STP T&#x0003e;C); and 5 SNPs in <italic>ATP1B2 </italic>(rs1641536, -<italic>8852T&#x0003e;C</italic>; rs1641535 -<italic>8703T&#x0003e;C</italic>; rs1624085 x2G&#x0003e;C; rs1641512, <italic>Ex7+414G&#x0003e;A</italic>).</p><p>Description and methods for each genotype assay can be found at [<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>]. Duplicated DNA pairs from 70 subjects in the study showed 100% concordance for all assays. Completion was &#x02265; 98% for all assays. We observed no significant departures from Hardy-Weinberg equilibrium in the control population.</p></sec><sec><title>Statistical Analyses</title><p>As an estimate of relative risk, odds ratios (OR) and their 95% confidence intervals (CI) were derived from unconditional logistic regression models that included dummy variables for the matching factors, i.e. age in 5 year categories and study site (Lodz or Warsaw). The association between genotypes and ovarian cancer risk was tested using a trend test, except for rare alleles in which heterozygous and homozygous variants were combined. We evaluated heterogeneity in the ORs observed for the genotype analysis on the basis of age, number of lifetime ovulatory cycles and family history of ovarian and/or breast cancer in first degree relatives, by introducing interaction terms in logistic regression models. Number of lifetime ovulatory cycles was used as a measure of a women's potential ovulatory life, and was calculated as previously described [<xref ref-type="bibr" rid="B11">11</xref>].</p><p>Pairwise linkage disequilibrium (LD) was estimated between SNPs based on D'and r<sup>2 </sup>values using Haploview [<xref ref-type="bibr" rid="B12">12</xref>]. Block structure was determined using genotype data from the control population, and the solid spline of LD option (D' threshold &#x0003e; 0.80). Haplotype frequencies within each block, ORs and their 95%CIs were estimated using HaploStats (version 1.2.1) [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>]. A global score statistic, adjusted for the matching factors age (in 5 year categories) and study site (Lodz or Warsaw), was used to evaluate the overall difference in haplotype frequencies between cases and controls.</p></sec></sec><sec><title>Results</title><p>The cases included in this analysis were diagnosed at a mean (SD) age of 56.2 (11.0) years. Tumor characteristics include: 45% had serous carcinomas, 62% had distal metastases, and 52% had tumors with poor grade of differentiation (Table <xref ref-type="table" rid="T1">1</xref>). As expected, serous, mixed and unclassified tumors were frequently poorly differentiated (69%, 75% and 90%, respectively), with a lower percentage of poorly differentiated tumors among endometriod (36%) and mucinous (19%) carcinomas. Compared to control women, cases were more frequently nulliparous or had fewer full-term births, had a larger number of lifetime ovulatory cycles, and more frequently reported a first degree family history of a first-degree relative with ovarian or breast cancer (Table <xref ref-type="table" rid="T1">1</xref>). Cases were also less likely to have used oral contraceptives. These differences were consistent with known or suspected risk factors for ovarian cancer [<xref ref-type="bibr" rid="B15">15</xref>].</p><p>A map of LD in the control population across the 10 SNPs evaluated is shown in Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>. Three of the evaluated polymorphisms (rs1641537, rs1641536 and rs1641535 in <italic>ATP1B1</italic>) showed strong correlations (pairwise r<sup>2 </sup>&#x0003e; 0.98) and, to avoid redundancy, only data for one of the correlated SNPs are shown in Table <xref ref-type="table" rid="T2">2</xref>. Genotypes with the variant alleles for the putative functional SNPs in <italic>SHBG</italic>, D356N (rs6259) and -67G&#x0003e;A 5'UTR (rs1799941), were less common among cases than controls; however, differences were not statistically significant (Table <xref ref-type="table" rid="T2">2</xref>). These two SNPs showed low correlation (r<sup>2 </sup>= 0.03). Evaluation of joint effects suggested that subjects with genotypes carrying variant alleles for both SNPs could be at particularly low risk (OR (95%CI) for subjects with the rs6259 AG/GG and rs1799941 AG/GG genotypes (9 cases and 36 controls) was 0.47 (0.22&#x02013;1.02), p = 0.06, compared to common homozygous for both SNPs (122 cases and 237 controls). However, the interaction between these two SNPs was not statistically significant (p = 0.15). None of the other SNPs evaluated were significantly associated with ovarian cancer risk. Associations with the SNPs evaluated in this report were not significantly modified by age, menopausal status, first degree family history of breast or ovarian cancer, or number of lifetime ovulatory cycles (data not shown). Associations were also not significantly modified by histological type or stage at diagnosis (data not shown).</p><p>Haplotype analyses including all non-redundant SNPs (i.e excluding rs1641536 and rs1641535 in <italic>ATP1B1</italic>) showed nine haplotypes with frequencies &#x0003e;0.01, with no significant overall association with ovarian cancer risk (global p = 0.42; Table <xref ref-type="table" rid="T3">3</xref>). Only one haplotype, present in 5% of cases and controls, carried the D356N (rs6259) SNP and showed no significant association with risk compared to the haplotype carrying the common alleles for each of the SNPs evaluated (ATACCCCG). Although none of the individual haplotypes were significantly associated with risk, there was a borderline significant association for the most common haplotype (frequent in 35% of controls) which carried a variant for a SNP in the 5'UTR of <italic>SHBG </italic>(rs1799941). Data were consistent with an inverse association for women carrying this haplotype (GTACCCCG) compared to the ATACCCCG haplotype (OR 95%CI = 0.77 (0.58&#x02013;1.01); Table <xref ref-type="table" rid="T3">3</xref>).</p></sec><sec><title>Discussion</title><p>This detailed evaluation of common genetic variation in <italic>SHBG </italic>including its neighboring gene <italic>ATP1B2</italic>, does not support a substantial association between common variants and ovarian cancer risk. However, the possibility of weak to modest associations could not be excluded.</p><p>The asparagine (N) allele of <italic>SHBG </italic>D356N and the variant allele of the -67G&#x0003e;A 5'UTR SNP in <italic>SHBG </italic>have been associated with elevated SHBG circulating levels [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B7">7</xref>]. Therefore, these SNP could result in a reduced bioavailability of estrogen or other sex-steroids, and a reduction in risk of hormonally-related cancers. Although the frequency of the genotypes with the variant alleles for these two SNPs was lower for cases than controls, differences were not statistically significant. A pentanucleotide (TAAAA)<sub>n </sub>repeat polymorphism, not measured in our study, has been found to be linked to the D356N SNP in Caucasian populations, as well as associated with elevated levels of SHBG [<xref ref-type="bibr" rid="B7">7</xref>]. Therefore, it is possible that functional changes not directly measured in our study might be related to risk. Given the lack of data from previous studies of ovarian cancer on the common variation in <italic>SHBG</italic>, further studies are needed to clarify potential relationships.</p><p>The main limitation of this study was limited power to detect weak to modest associations. Specifically, the study size provided 80% power to detect ORs of 1.5 or 0.7 for MAFs ranging from 0.10 to 0.50, assuming an additive mode of inheritance; and MAFs ranging from 0.20 to 0.35, assuming a dominant inheritance. However, the power to detect associations for MAF outside these ranges, recessive associations, or gene-gene/gene-environment interactions was low. Therefore, such associations could have missed in our study.</p><p>This population-based study has among the highest participation rate attained in population-based studies with collection of biological specimens. However, collection of DNA samples inevitably reduces overall participation rates and could introduce selection bias. This bias is unlikely to be of relevance in this report because the evaluated SNPs are unlikely to be related to potential selection factors. Further, the observed allele frequency for the <italic>SHBG </italic>D356N was similar to previously published studies among Caucasians [<xref ref-type="bibr" rid="B6">6</xref>], and the distribution of ovarian cancer risk factors in cases and controls was consistent with known or suspected risk factors for ovarian cancer [<xref ref-type="bibr" rid="B15">15</xref>].</p></sec><sec><title>Conclusion</title><p>This report of a detailed assessment of genetic variation in <italic>SHBG </italic>including its neighboring gene <italic>ATP1B2</italic>, does not support a substantial association between common variation in this region and ovarian cancer risk. However, weak or modest associations could not be excluded, particularly a reduced risk of ovarian cancer hypothesized for the functional SNPs D356N and -67G&#x0003e;A 5'UTR. Therefore, further evaluation in larger study populations is warranted.</p></sec><sec><title>Abbreviations</title><p><bold><italic>ATP1B2 </italic></bold>&#x02013; ATPase, Na+/K+ transporting beta 2 polypeptide</p><p><bold>CI </bold>&#x02013; confidence interval</p><p><bold>LD </bold>&#x02013; linkage disequilibrium</p><p><bold>LRT </bold>&#x02013; likelihood ratio test</p><p><bold>MAF </bold>&#x02013; minor allele frequency</p><p><bold>OR </bold>&#x02013; odds ratio</p><p><bold><italic>SHBG </italic></bold>&#x02013; sex hormone-binding globulin</p><p><bold>SNP </bold>&#x02013; single nucleotide polymorphisms</p><p><bold><italic>TP53 </italic></bold>&#x02013; tumor protein p53 (Li-Fraumeni syndrome)</p></sec><sec><title>Competing interests</title><p>The author(s) declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>MG-C participated in the design of the study and data collection, performed the statistical analysis and wrote the paper; MY, LB, RW and SJC participated in the selection and performance of genotyping assays; LAB, JL, NS-D, BP, A B-M, WZ participated in the design of the study and data collection; MES participated in the design of the study and carried out the pathology review; YQ and DR helped with the statistical analyses. All authors were involved in the drafting of the manuscript, read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/7/60/prepub"/></p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional File 1</title><p>Supplementary Figure 1: Patterns of linkage disequilibrium across the <italic>SHBG </italic>and its 3' neighbor gene <italic>ATP1B2</italic>. The figure provided shows Patterns of linkage disequilibrium across the <italic>SHBG </italic>and its 3' neighbor gene <italic>ATP1B2</italic>.</p></caption><media xlink:href="1471-2407-7-60-S1.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><ack><sec><title>Acknowledgements</title><p>This research was supported by the Intramural Research Program of the NIH, National Cancer Institute, Division of Cancer Epidemiology and Genetics and the Center for Cancer Research. We thank Anita Soni (Westat, Rockville, MD) for her work on study management for the Polish ovarian cancer study; Pei Chao (IMS, Silver Spring, MD) for her work on data and sample management; and physicians, nurses, interviewers and study participants for their efforts during filed-work.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Risch</surname><given-names>HA</given-names></name></person-group><article-title>Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone</article-title><source>J Natl Cancer Inst</source><year>1998</year><volume>90</volume><fpage>1774</fpage><lpage>1786</lpage><pub-id pub-id-type="pmid">9839517</pub-id><pub-id pub-id-type="doi">10.1093/jnci/90.23.1774</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lukanova</surname><given-names>A</given-names></name><name><surname>Lundin</surname><given-names>E</given-names></name><name><surname>Akhmedkhanov</surname><given-names>A</given-names></name><name><surname>Micheli</surname><given-names>A</given-names></name><name><surname>Rinaldi</surname><given-names>S</given-names></name><name><surname>Zeleniuch-Jacquotte</surname><given-names>A</given-names></name><name><surname>Lenner</surname><given-names>P</given-names></name><name><surname>Muti</surname><given-names>P</given-names></name><name><surname>Biessy</surname><given-names>C</given-names></name><name><surname>Krogh</surname><given-names>V</given-names></name><name><surname>Berrino</surname><given-names>F</given-names></name><name><surname>Hallmans</surname><given-names>G</given-names></name><name><surname>Riboli</surname><given-names>E</given-names></name><name><surname>Kaaks</surname><given-names>R</given-names></name><name><surname>Toniolo</surname><given-names>P</given-names></name></person-group><article-title>Circulating levels of sex steroid hormones and risk of ovarian cancer</article-title><source>Int J Cancer</source><year>2003</year><volume>104</volume><fpage>636</fpage><lpage>642</lpage><pub-id pub-id-type="pmid">12594820</pub-id><pub-id pub-id-type="doi">10.1002/ijc.10990</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Helzlsouer</surname><given-names>KJ</given-names></name><name><surname>Alberg</surname><given-names>AJ</given-names></name><name><surname>Gordon</surname><given-names>GB</given-names></name><name><surname>Longcope</surname><given-names>C</given-names></name><name><surname>Bush</surname><given-names>TL</given-names></name><name><surname>Hoffman</surname><given-names>SC</given-names></name><name><surname>Comstock</surname><given-names>GW</given-names></name></person-group><article-title>Serum gonadotropins and steroid hormones and the development of ovarian cancer</article-title><source>JAMA</source><year>1995</year><volume>274</volume><fpage>1926</fpage><lpage>1930</lpage><pub-id pub-id-type="pmid">8568986</pub-id><pub-id pub-id-type="doi">10.1001/jama.274.24.1926</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Selby</surname><given-names>C</given-names></name></person-group><article-title>Sex hormone binding globulin: origin, function and clinical significance</article-title><source>Ann Clin Biochem</source><year>1990</year><volume>27 ( Pt 6)</volume><fpage>532</fpage><lpage>541</lpage><pub-id pub-id-type="pmid">2080856</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cousin</surname><given-names>P</given-names></name><name><surname>Calemard-Michel</surname><given-names>L</given-names></name><name><surname>Lejeune</surname><given-names>H</given-names></name><name><surname>Raverot</surname><given-names>G</given-names></name><name><surname>Yessaad</surname><given-names>N</given-names></name><name><surname>Emptoz-Bonneton</surname><given-names>A</given-names></name><name><surname>Morel</surname><given-names>Y</given-names></name><name><surname>Pugeat</surname><given-names>M</given-names></name></person-group><article-title>Influence of SHBG gene pentanucleotide TAAAA repeat and D327N polymorphism on serum sex hormone-binding globulin concentration in hirsute women</article-title><source>J Clin Endocrinol Metab</source><year>2004</year><volume>89</volume><fpage>917</fpage><lpage>924</lpage><pub-id pub-id-type="pmid">14764814</pub-id><pub-id pub-id-type="doi">10.1210/jc.2002-021553</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dunning</surname><given-names>AM</given-names></name><name><surname>Dowsett</surname><given-names>M</given-names></name><name><surname>Healey</surname><given-names>CS</given-names></name><name><surname>Tee</surname><given-names>L</given-names></name><name><surname>Luben</surname><given-names>RN</given-names></name><name><surname>Folkerd</surname><given-names>E</given-names></name><name><surname>Novik</surname><given-names>KL</given-names></name><name><surname>Kelemen</surname><given-names>L</given-names></name><name><surname>Ogata</surname><given-names>S</given-names></name><name><surname>Pharoah</surname><given-names>PD</given-names></name><name><surname>Easton</surname><given-names>DF</given-names></name><name><surname>Day</surname><given-names>NE</given-names></name><name><surname>Ponder</surname><given-names>BA</given-names></name></person-group><article-title>Polymorphisms associated with circulating sex hormone levels in postmenopausal women</article-title><source>J Natl Cancer Inst</source><year>2004</year><volume>96</volume><fpage>936</fpage><lpage>945</lpage><pub-id pub-id-type="pmid">15199113</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haiman</surname><given-names>CA</given-names></name><name><surname>Riley</surname><given-names>SE</given-names></name><name><surname>Freedman</surname><given-names>ML</given-names></name><name><surname>Setiawan</surname><given-names>VW</given-names></name><name><surname>Conti</surname><given-names>DV</given-names></name><name><surname>Le Marchand</surname><given-names>L</given-names></name></person-group><article-title>Common genetic variation in the sex steroid hormone-binding globulin (SHBG) gene and circulating shbg levels among postmenopausal women: the Multiethnic Cohort</article-title><source>J Clin Endocrinol Metab</source><year>2005</year><volume>90</volume><fpage>2198</fpage><lpage>2204</lpage><pub-id pub-id-type="pmid">15634719</pub-id><pub-id pub-id-type="doi">10.1210/jc.2004-1417</pub-id></citation></ref><ref id="B8"><citation citation-type="other"><person-group person-group-type="author"><name><surname>A</surname><given-names>L</given-names></name><name><surname>L</surname><given-names>B</given-names></name><name><surname>YM</surname><given-names>LV</given-names></name><name><surname>S</surname><given-names>P</given-names></name><collab>Gerhadt D</collab><collab>Tarazona-Santos</collab><name><surname>D</surname><given-names>GR</given-names></name><name><surname>PE</surname><given-names>L</given-names></name><name><surname>VN</surname><given-names>K</given-names></name><name><surname>S</surname><given-names>C</given-names></name></person-group><article-title>Pattern of genetic variation in the TP53 locus indicates linkage disequilibrium extends across the flanking genes, ATP1B2 and WDR79</article-title><year>2007</year></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>BR</surname><given-names>P</given-names></name><collab>Yeager M</collab><name><surname>L</surname><given-names>B</given-names></name><name><surname>R</surname><given-names>W</given-names></name><name><surname>M</surname><given-names>B</given-names></name><name><surname>L</surname><given-names>Q</given-names></name><collab>Sicotte H</collab><name><surname>B</surname><given-names>S</given-names></name><name><surname>M</surname><given-names>A</given-names></name><name><surname>A</surname><given-names>C</given-names></name><name><surname>A</surname><given-names>E</given-names></name><name><surname>V</surname><given-names>P</given-names></name><name><surname>DS</surname><given-names>G</given-names></name><name><surname>SJ</surname><given-names>C</given-names></name></person-group><article-title>SNP500Cancer: A Public Resource for Sequence Validation, Assay Development, and Frequency Analysis for Genetic Variation in Candidate Genes</article-title><source>Nuc Acids Res</source><year>2006</year><volume>34 (Database Issue)</volume><fpage>D617</fpage><lpage>D621</lpage></citation></ref><ref id="B10"><citation citation-type="other"><year>2007</year><ext-link ext-link-type="uri" xlink:href="http://snp500cancer.nci.nih.gov"/></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Webb</surname><given-names>PM</given-names></name><name><surname>Green</surname><given-names>A</given-names></name><name><surname>Cummings</surname><given-names>MC</given-names></name><name><surname>Purdie</surname><given-names>DM</given-names></name><name><surname>Walsh</surname><given-names>MD</given-names></name><name><surname>Chenevix-Trench</surname><given-names>G</given-names></name></person-group><article-title>Relationship between number of ovulatory cycles and accumulation of mutant p53 in epithelial ovarian cancer</article-title><source>J Natl Cancer Inst</source><year>1998</year><volume>90</volume><fpage>1729</fpage><lpage>1734</lpage><pub-id pub-id-type="pmid">9827528</pub-id><pub-id pub-id-type="doi">10.1093/jnci/90.22.1729</pub-id></citation></ref><ref id="B12"><citation citation-type="other"><year>2007</year><ext-link ext-link-type="uri" xlink:href="http://www.broad.mit.edu/mpg/haploview/index.php"/></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schaid</surname><given-names>DJ</given-names></name></person-group><article-title>Evaluating associations of haplotypes with traits</article-title><source>Genet Epidemiol</source><year>2004</year><volume>27</volume><fpage>348</fpage><lpage>364</lpage><pub-id pub-id-type="pmid">15543638</pub-id><pub-id pub-id-type="doi">10.1002/gepi.20037</pub-id></citation></ref><ref id="B14"><citation citation-type="other"><year>2007</year><ext-link ext-link-type="uri" xlink:href="http://mayoresearch.mayo.edu/mayo/research/biostat/schaid.cfm"/></citation></ref><ref id="B15"><citation citation-type="book"><person-group person-group-type="author"><name><surname>NS</surname><given-names>W</given-names></name><name><surname>LS</surname><given-names>C</given-names></name><name><surname>DC</surname><given-names>F</given-names></name><name><surname>KA</surname><given-names>R</given-names></name></person-group><person-group person-group-type="editor"><name><surname>D S and JF F</surname></name></person-group><article-title>Ovarian Cancer</article-title><source>Cancer Epidemiology and Prevention</source><year>1996</year><publisher-name>New York, Oxford University Press</publisher-name><fpage>1040</fpage><lpage>1057</lpage></citation></ref></ref-list><sec sec-type="display-objects"><title>Figures and Tables</title><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Personal and tumor characteristics of 264 ovarian cancer cases and 625 controls in the Polish Ovarian Cancer Study.</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center">Cases* N = 264</td><td></td><td align="center">Controls* N = 625</td><td></td><td align="center">P**</td></tr></thead><tbody><tr><td align="left" colspan="6">Study site, N %</td></tr><tr><td align="left">&#x02003;Warsaw</td><td align="center">177</td><td align="center">67%</td><td align="center">423</td><td align="center">68%</td><td align="center">0.85</td></tr><tr><td align="left">&#x02003;Lodz</td><td align="center">87</td><td align="center">33%</td><td align="center">202</td><td align="center">32%</td><td></td></tr><tr><td align="left">Age, mean SD in years</td><td align="center">56.3</td><td align="center">10.8</td><td align="center">56.1</td><td align="center">10.8</td><td align="center">0.83</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left" colspan="6">No. of full-term births, N %</td></tr><tr><td align="left">&#x02003;Nulliparous</td><td align="center">50</td><td align="center">19%</td><td align="center">79</td><td align="center">13%</td><td align="center">&#x0003c;0.0001</td></tr><tr><td align="left">&#x02003;1</td><td align="center">101</td><td align="center">38%</td><td align="center">176</td><td align="center">28%</td><td></td></tr><tr><td align="left">&#x02003;2</td><td align="center">94</td><td align="center">36%</td><td align="center">273</td><td align="center">44%</td><td></td></tr><tr><td align="left">&#x02003;&#x02265; 3</td><td align="center">19</td><td align="center">7%</td><td align="center">97</td><td align="center">16%</td><td></td></tr><tr><td align="left">Number of ovulatory cycles, mean SD</td><td align="center">410.9</td><td align="center">71.1</td><td align="center">398.1</td><td align="center">81.3</td><td align="center">0.03</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left" colspan="6">Use of oral contraceptive, N %</td></tr><tr><td align="left">&#x02003;Never</td><td align="center">245</td><td align="center">94%</td><td align="center">556</td><td align="center">90%</td><td align="center">0.08</td></tr><tr><td align="left">&#x02003;Ever</td><td align="center">16</td><td align="center">6%</td><td align="center">60</td><td align="center">10%</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left" colspan="6">Currently having menstrual periods, N %</td></tr><tr><td align="left">&#x02003;No</td><td align="center">182</td><td align="center">71%</td><td align="center">401</td><td align="center">66%</td><td align="center">0.40</td></tr><tr><td align="left">&#x02003;Yes</td><td align="center">75</td><td align="center">29%</td><td align="center">203</td><td align="center">34%</td><td></td></tr><tr><td align="left">&#x02003;Unclear</td><td align="center">7</td><td align="center">3%</td><td align="center">20</td><td align="center">3%</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left" colspan="6">Use of oral hormone replacement therapy among post-menopausal women</td></tr><tr><td align="left">&#x02003;Never</td><td align="center">146</td><td align="center">81%</td><td align="center">325</td><td align="center">82%</td><td></td></tr><tr><td align="left">&#x02003;Ever</td><td align="center">35</td><td align="center">19%</td><td align="center">70</td><td align="center">18%</td><td align="center">0.15</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left" colspan="6">Family history of breast or ovarian cancer in first-degree relatives, N %</td></tr><tr><td align="left">&#x02003;No</td><td align="center">210</td><td align="center">80%</td><td align="center">553</td><td align="center">88%</td><td align="center">0.001</td></tr><tr><td align="left">&#x02003;Breast cancer only</td><td align="center">26</td><td align="center">10%</td><td align="center">24</td><td align="center">4%</td><td></td></tr><tr><td align="left">&#x02003;Ovarian cancer only</td><td align="center">26</td><td align="center">10%</td><td align="center">40</td><td align="center">6%</td><td></td></tr><tr><td align="left">&#x02003;Both</td><td align="center">2</td><td align="center">1%</td><td align="center">8</td><td align="center">1%</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left" colspan="6"><bold>Tumor Characteristics</bold></td></tr><tr><td align="left" colspan="6">Histology, N (%)</td></tr><tr><td align="left">&#x02003;Serous</td><td align="center">118</td><td align="center">45%</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Mucinous</td><td align="center">26</td><td align="center">10%</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Endometrioid</td><td align="center">58</td><td align="center">22%</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Clear cell</td><td align="center">14</td><td align="center">5%</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Mixed</td><td align="center">18</td><td align="center">7%</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Others or unclassified</td><td align="center">30</td><td align="center">11%</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">Stage, N % distant</td><td align="center">110</td><td align="center">62%</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Not staged or missing</td><td align="center">86</td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left" colspan="6">Grade of differentiation, N %</td></tr><tr><td align="left">&#x02003;Well</td><td align="center">21</td><td align="center">13%</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Moderate</td><td align="center">59</td><td align="center">35%</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Poor</td><td align="center">88</td><td align="center">52%</td><td></td><td></td><td></td></tr><tr><td align="left">&#x02003;Missing</td><td align="center">96</td><td></td><td></td><td></td><td></td></tr></tbody></table><table-wrap-foot><p>* Differences between the total number of cases and controls and frequencies shown in the table are due to missing data.</p><p>** P values for categorical variables are based on chi squared tests, and on t-tests for continuous variables.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Risk of epithelial ovarian cancer and polymorphisms in <italic>SHBG </italic>and its 3' neighbor <italic>ATP1B2</italic>, among 264 ovarian cancer cases and 625 controls in the Polish Ovarian Cancer Study*</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left">Gene SNP</td><td></td><td align="right">Cases</td><td align="right">Controls</td><td align="right">OR**</td><td align="center">95% CI</td><td align="right">P-trend</td></tr></thead><tbody><tr><td align="left"><bold><italic>SHBG</italic></bold></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">rs1799941</td><td align="center">AA</td><td align="right">144</td><td align="right">278</td><td align="right">1.00</td><td></td><td></td></tr><tr><td align="left">-67G&#x0003e;A</td><td align="center">AG</td><td align="right">118</td><td align="right">287</td><td align="right">0.79</td><td align="center">0.59 &#x02013; 1.07</td><td></td></tr><tr><td align="left">5'UTR</td><td align="center">GG</td><td align="right">23</td><td align="right">57</td><td align="right">0.79</td><td align="center">0.46 &#x02013; 1.33</td><td align="right">0.14</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">rs6257</td><td align="center">TT</td><td align="right">242</td><td align="right">520</td><td align="right">1.00</td><td></td><td></td></tr><tr><td align="left">IVS1-17T&#x0003e;C</td><td align="center">TC</td><td align="right">41</td><td align="right">91</td><td align="right">0.97</td><td align="center">0.65 &#x02013; 1.44</td><td></td></tr><tr><td></td><td align="center">CC</td><td align="right">2</td><td align="right">2</td><td align="right">2.13</td><td align="center">0.29 &#x02013; 15.3</td><td align="right">0.75</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">rs6259</td><td align="center">AA</td><td align="right">254</td><td align="right">547</td><td align="right">1.00</td><td></td><td></td></tr><tr><td align="left">Ex8+6G&#x0003e;A</td><td align="center">AG</td><td align="right">30</td><td align="right">72</td><td align="right">0.89</td><td align="center">0.57 &#x02013; 1.40</td><td></td></tr><tr><td align="left">D356N</td><td align="center">GG</td><td align="right">1</td><td align="right">4</td><td align="right">0.51</td><td align="center">0.06 &#x02013; 4.65</td><td align="right">0.72</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">rs727428</td><td align="center">CC</td><td align="right">119</td><td align="right">264</td><td align="right">1.00</td><td></td><td></td></tr><tr><td align="left">1121 bp 3' of STP T&#x0003e;C</td><td align="center">CT</td><td align="right">121</td><td align="right">278</td><td align="right">0.96</td><td align="center">0.71 &#x02013; 1.30</td><td></td></tr><tr><td></td><td align="center">TT</td><td align="right">45</td><td align="right">81</td><td align="right">1.25</td><td align="center">0.81 &#x02013; 1.91</td><td align="right">0.48</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">rs1641544</td><td align="center">CC</td><td align="right">261</td><td align="right">580</td><td align="right">1.00</td><td></td><td></td></tr><tr><td align="left">31959 bp 3' of STP T&#x0003e;C</td><td align="center">CT</td><td align="right">22</td><td align="right">38</td><td align="right">1.34</td><td align="center">0.77 &#x02013; 2.33</td><td align="right">0.30</td></tr><tr><td></td><td align="center">TT</td><td align="right">1</td><td align="right">0</td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><bold><italic>ATP1B2</italic></bold></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">rs1641537 ***</td><td align="center">CC</td><td align="right">215</td><td align="right">486</td><td align="right">1.00</td><td></td><td></td></tr><tr><td align="left">-9115T&#x0003e;C</td><td align="center">CT</td><td align="right">66</td><td align="right">125</td><td align="right">1.21</td><td align="center">0.86 &#x02013; 1.71</td><td></td></tr><tr><td></td><td align="center">TT</td><td align="right">3</td><td align="right">8</td><td align="right">0.90</td><td align="center">0.23 &#x02013; 3.46</td><td align="right">0.36</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">rs1624085</td><td align="center">CC</td><td align="right">116</td><td align="right">246</td><td align="right">1.00</td><td></td><td></td></tr><tr><td align="left">Ex2G&#x0003e;C</td><td align="center">CG</td><td align="right">120</td><td align="right">292</td><td align="right">0.86</td><td align="center">0.64 &#x02013; 1.18</td><td></td></tr><tr><td></td><td align="center">GG</td><td align="right">49</td><td align="right">84</td><td align="right">1.25</td><td align="center">0.82 &#x02013; 1.90</td><td align="right">0.60</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left">rs1641512</td><td align="center">GG</td><td align="right">193</td><td align="right">401</td><td align="right">1.00</td><td></td><td></td></tr><tr><td align="left">Ex7+414G&#x0003e;A</td><td align="center">GA</td><td align="right">80</td><td align="right">195</td><td align="right">0.86</td><td align="center">0.63 &#x02013; 1.17</td><td></td></tr><tr><td></td><td align="center">AA</td><td align="right">12</td><td align="right">27</td><td align="right">0.94</td><td align="center">0.46 &#x02013; 1.90</td><td align="right">0.42</td></tr></tbody></table><table-wrap-foot><p>* Differences between the total number of cases and controls and frequencies shown in the table are due to missing genotype data.</p><p>** Adjusted for age and city.</p><p>*** Highly correlated with <italic>ATP1B1 </italic>rs1641536 (18852T&#x0003e;C) and rs1641535 (-8703T&#x0003e;c), r<sup>2 </sup>&#x0003e; 0.98, not shown in table to avoid redundancy.</p></table-wrap-foot></table-wrap><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Risk of epithelial ovarian cancer and <italic>SHBG-ATP1B2 </italic>extended haploptypes, among 264 ovarian cancer cases and 625 controls in the Polish Ovarian Cancer Study</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td align="center" colspan="2">Haplotype frequency</td><td align="center">OR</td><td align="center">95%CI</td><td align="center">P</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td colspan="2"><hr></hr></td><td></td><td></td><td></td></tr><tr><td align="center" colspan="8">Haplotypes*</td><td align="center">Cases</td><td align="center">Controls</td><td></td><td></td><td></td></tr></thead><tbody><tr><td align="center">A</td><td align="center">T</td><td align="center">A</td><td align="center">C</td><td align="center">C</td><td align="center">C</td><td align="center">C</td><td align="center">G</td><td align="center">0.26</td><td align="center">0.20</td><td align="center">1.00</td><td align="center">(reference**)</td><td></td></tr><tr><td align="center">G</td><td align="center">.</td><td align="center">.</td><td align="center">.</td><td align="center">.</td><td align="center">.</td><td align="center">.</td><td align="center">.</td><td align="center">0.32</td><td align="center">0.35</td><td align="center">0.77</td><td align="center">0.58 &#x02013; 1.01</td><td align="center">0.06</td></tr><tr><td align="center">.</td><td align="center">.</td><td align="center">.</td><td align="center">.</td><td align="center">.</td><td align="center">.</td><td align="center">G</td><td align="center">A</td><td align="center">0.01</td><td align="center">0.02</td><td align="center">0.43</td><td align="center">0.14 &#x02013; 1.33</td><td align="center">0.14</td></tr><tr><td align="center">.</td><td align="center">.</td><td align="center">.</td><td align="center">T</td><td align="center">.</td><td align="center">.</td><td align="center">G</td><td align="center">.</td><td align="center">0.12</td><td align="center">0.11</td><td align="center">0.89</td><td align="center">0.60 &#x02013; 1.33</td><td align="center">0.58</td></tr><tr><td align="center">.</td><td align="center">.</td><td align="center">.</td><td align="center">T</td><td align="center">.</td><td align="center">T</td><td align="center">G</td><td align="center">A</td><td align="center">0.09</td><td align="center">0.09</td><td align="center">0.83</td><td align="center">0.56 &#x02013; 1.23</td><td align="center">0.36</td></tr><tr><td align="center">.</td><td align="center">.</td><td align="center">.</td><td align="center">T</td><td align="center">T</td><td align="center">T</td><td align="center">G</td><td align="center">A</td><td align="center">0.04</td><td align="center">0.03</td><td align="center">1.22</td><td align="center">0.70 &#x02013; 2.12</td><td align="center">0.49</td></tr><tr><td align="center">.</td><td align="center">.</td><td align="center">G</td><td align="center">T</td><td align="center">.</td><td align="center">.</td><td align="center">G</td><td align="center">A</td><td align="center">0.05</td><td align="center">0.05</td><td align="center">0.81</td><td align="center">0.50 &#x02013; 1.30</td><td align="center">0.38</td></tr><tr><td align="center">.</td><td align="center">C</td><td align="center">.</td><td align="center">T</td><td align="center">.</td><td align="center">.</td><td align="center">G</td><td align="center">.</td><td align="center">0.07</td><td align="center">0.07</td><td align="center">0.81</td><td align="center">0.53 &#x02013; 1.25</td><td align="center">0.34</td></tr><tr><td align="center">G</td><td align="center">.</td><td align="center">.</td><td align="center">.</td><td align="center">.</td><td align="center">.</td><td align="center">G</td><td align="center">.</td><td align="center">0.01</td><td align="center">0.02</td><td align="center">0.51</td><td align="center">0.17 &#x02013; 1.58</td><td align="center">0.24</td></tr><tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="right" colspan="13">Global p = 0.42</td></tr></tbody></table><table-wrap-foot><p>* Polymorphic bases in 5' to 3' order: <italic>SHBG </italic>(rs1799941, rs6257, rs6259, rs727428, rs1641544); <italic>ATP1B2 </italic>(rs16441537, rs1624085, rs1641512). Two <italic>ATP1B2 </italic>SNPs (rs1641536 and rs1641535) highly correlated (r<sup>2 </sup>&#x0003e; 0.98) with rs1641537 are not included in the analyses.</p><p>** The reference</p></table-wrap-foot></table-wrap></sec></back></article> 